Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.1% and the iShares Biotechnology ETF (IBB) was down 0.4%.
Edgewise Therapeutics (EWTX) shares soared 14% after it said a phase 2 trial of sevasemten to treat patients with Becker muscular dystrophy met its primary endpoint of change from baseline in creatine kinase.
PureTech Health (PRTC) shares jumped 13% after it said that a phase 2 clinical trial of its drug deupirfenidone as a treatment of patients with idiopathic pulmonary fibrosis reached its primary endpoint.
Foghorn Therapeutics (FHTX) shares fell 17% after it said it has decided to discontinue the independent development of FHD-286 in combination with decitabine to treat patients with relapsed and/or refractory acute myeloid leukemia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。